endpts.com·Apr 23, 2026
Regeneron has received FDA approval for the first gene therapy aimed at treating a rare inherited form of hearing loss, and has also finalized a pricing agreement in the U.S.
Regeneron has achieved a significant milestone by securing the first FDA approval for a gene therapy targeting a rare form of inherited hearing loss. This development highlights the growing potential and regulatory acceptance of gene therapies, indicating a promising area for investment and innovation in the biotech sector.